Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Jan 31, 2019 → May 11, 2022
NCT ID
NCT03497689About Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil is a approved stage product being developed by United Therapeutics for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03497689. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03497689 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension